Literature DB >> 3282358

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.

G Hale1, S Cobbold, H Waldmann.   

Abstract

A total of 282 patients with leukemia have been treated by transplantation from HLA-matched siblings using marrow depleted of T cells with CAMPATH-1 and autologous complement. The incidence of graft-versus-host disease (GVHD) of grades 2-4 was only 12% but the maximum incidence of graft failure was 15%. A significant increase in relapse cannot yet be detected in acute leukemia but relapse in chronic granulocytic leukemia (CGL) was substantially above that reported before T cell depletion. The most important predictive factor for relapse in CGL appeared to be slow engraftment. This finding suggests an alternative explanation for the graft-versus-leukemia effect other than a direct attack on leukemia cells. This is that donor T cells may affect the balance of competition between donor and recipient haemopoesis by preventing a rejection reaction to donor stem cells. Recipient leukemic cells would benefit (i.e. relapse) if recipient hemopoiesis gained an advantage. If this explanation were true we would expect extra immunosuppressive preconditioning of recipients to reduce the incidence of relapse, as well as preventing graft rejection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282358     DOI: 10.1097/00007890-198804000-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  22 in total

Review 1.  Graft versus leukemia.

Authors:  A Butturini; R P Gale
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 2.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

Review 3.  Intestinal graft-versus-host disease: mechanisms and management.

Authors:  Hiroyuki Takatsuka; Tsuyoshi Iwasaki; Takahiro Okamoto; Eizo Kakishita
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  In vitro hemopoiesis in human micro long-term bone marrow cultures recharged with either allogeneic, T-cell-depleted allogeneic, or syngeneic bone marrow cells.

Authors:  H G Mergenthaler; P Dörmer
Journal:  Blut       Date:  1990-04

Review 5.  Current and emerging strategies for the prevention of graft-versus-host disease.

Authors:  Sung Won Choi; Pavan Reddy
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

Review 6.  Bone marrow transplantation. Part I--Allogeneic.

Authors:  N J Chao; K G Blume
Journal:  West J Med       Date:  1989-12

Review 7.  Recent advances in the treatment of graft-versus-host disease.

Authors:  Tsuyoshi Iwasaki
Journal:  Clin Med Res       Date:  2004-11

8.  Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.

Authors:  M Q Xia; G Hale; M R Lifely; M A Ferguson; D Campbell; L Packman; H Waldmann
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

Review 9.  Role of interleukin-2 in human hematological malignancies.

Authors:  A Toren; A Ackerstein; S Slavin; A Nagler
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

10.  Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation.

Authors:  Erin Gatza; Sung Won Choi
Journal:  Int J Hematol Oncol       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.